Trastuzumab and Lung Cancer

A naked antibody alone just doesn't cut it in terms of response rate and survival. In lung cancer, we've seen the my pathway study showing some response in the 10 to 20 percent range with Trastuzumab-Tutuzumab. There may be more combinations that could be exploited to render a more durable response.